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Abstract
The ATP-binding cassette (ABC) transporter superfamily is a large gene family that has been highly conserved throughout evolution. The
physiological importance of these membrane transporters is highlighted by the large variety of substrates they transport, and by the
observation that mutations in many of them cause heritable diseases in human. Likewise, overexpression of certain ABC transporters, such as
P-glycoprotein and members of the multidrug resistance associated protein (MRP) family, is associated with multidrug resistance in various
cells and organisms. Understanding the structure and molecular mechanisms of transport of the ABC transporters in normal tissues and their
possibly altered function in human diseases requires large amounts of purified and active proteins. For this, efficient expression systems are
needed. The methylotrophic yeast Pichia pastoris has proven to be an efficient and inexpensive experimental model for high-level expression
of many proteins, including ABC transporters. In the present review, we will summarize recent advances on the use of this system for the
expression, purification, and functional characterization of P-glycoprotein and two members of the MRP subfamily.
D 2003 Elsevier Science B.V. All rights reserved.
Keywords: ATP-binding cassette transporter; Pichia pastoris
1. Introduction
The ATP-binding cassette (ABC) transporter superfamily
is a large gene family that has been highly conserved
through evolution from bacteria to humans, including 51
members in human, 55 in fly, 129 in plants, and over 300 in
bacteria so far. These integral membrane proteins use ATP
hydrolysis to energize the transport of a large variety of
molecules, ranging from proteins to ions. Many excellent
reviews and books on the phylogeny, structure, function,
and mechanisms of action of prokaryotic and eukaryotic
ABC transporters have been published [1–8], and readers
are referred to those for background information. This
review will solely deal with the use of the yeast Pichia
pastoris for expression, purification, and functional charac-
terization of three mammalian ABC transporters, with
emphasis on unique aspects of this host for expression
and purification studies.
ABC transporters generally share a common structural/
functional unit, consisting of one nucleotide-binding domain
(NBD) associated with a membrane-spanning domain
(MSD) comprising six transmembrane (TM) a-helices. In
eukaryotes, a functional ABC transporter is often composed
of a duplication of this unit, either as a homodimer fused in
a single molecule containing two NBDs and two MSDs (e.g.
P-glycoprotein), or as two heterologous half transporters
(e.g. ABCB2/3, ABCG5/8). In general, eukaryotic ABC
transporters are structurally organized in the order of amino
(N) terminus–MSD1–NBD1–MSD2–NBD2–carboxyl
(C) terminus in a single molecule (Fig. 1A), although an
extra N-terminal membrane-spanning domain (MSD0) fol-
lowed by a cytoplasmic linker region (L0) is found in some
members of the family (Fig. 1C). The relative position of
NBDs can be inversed and found amino terminally to the
first TM segment (e.g. members in ABCG subfamily). On
the other hand, in most ABC transporters from bacteria,
NBDs, MSDs, and substrate-binding proteins (SBPs) are
separate polypeptides that assemble at the membrane to
form a single transporter [9,10]. All ABC proteins are
defined by the presence of the hallmark consensus Walker
A [GX4GK(S/T)] and Walker B (hyd4D, where hyd = hy-
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drophobic amino acid residues) sequence motifs in each
NBD, in addition to the highly conserved signature motif
(LSGGQKQRIAIA) known as the ABC motif [8]. NBDs
are the most conserved regions of ABC transporters, and
detailed multiple sequence alignments of these NBDs from
over 250 sequences have recently been published [11]. In
contrast to the NBDs, sequence conservation in the MSDs
of ABC transporters is modest. The exact number, position,
and polarity of TM segments have been studied carefully
only in a few ABC transporters, such as P-gp [12] and
MRP1 [13,14], and these studies agree with hydropathy
profiling, strongly supporting a 2 6 TM arrangement in
the MSDs. Recently, a structure at 4.5-A˚ resolution of the
Escherichia coli ABC transporter MsbA homodimer
[2 (MSD–NBD)], has been obtained by X-ray crystallog-
raphy, confirming the presence of six TM helices in each
MSD of the ABC transporter [15]. Interestingly, a distinct
overall structure has been observed for another E. coli ABC
transporter, BtuCD, which mediates cellular uptake of
vitamin B12 [16]. The transporter is composed of two
membrane subunits (2BtuC) and two ABC subunits
(2BtuD). A crystal structure at resolution of 3.2 A˚ shows
that, unlike most ABC transporters, the membrane subunit
(BtuC) contains 10 TM a-helices instead of six. The
tetramer 2 (BtuCD) forms a large translocation channel
between the subunits [16]. The predicted intracellular loops
that join certain pairs of TM segments in P-gp show a
significant degree of sequence similarity. Although their role
in the transport process remains largely unknown, their
importance is highlighted by the detrimental effect of
mutations in such segments (reviewed in Ref. [3]). Based
on the similarity in sequence and organization of the NBDs,
the human ABC transporter proteins have been classified
into seven distinct subfamilies, namely ABCA to ABCG,
each composed of a number of closely related genes [7]
[http://humanabc.4t.com/humanabc.htm]. Mutations in
many of the ABC transporters are found to be associated
with various genetic disorders and pathological conditions
Fig. 1. Schematic diagrams of the membrane topology of ABC transporters. (A) Typical four-domain core structure (MSD1–NBD1–MSD2–NBD2) of P-
glycoprotein (P-gp). (B) Membrane topology of some members of the ABCC subfamily that contain only the core structure with an extra N-terminal
cytoplasmic region (L0), as in MRP4, MRP5, and CFTR. The regulatory ‘‘R’’ domain of CFTR in the L1 region is depicted as dashed lines. (C) Membrane
topology of MRP1 and its close relatives that contain the additional N-terminal MSD (MDS0). The orientation of the lipid membrane bilayer is indicated.
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in humans [8]. For example, cystic fibrosis (CFTR/ABCC7)
[17], Dubin–Johnson syndrome (cMOAT/MRP2/ABCC2)
[18], progressive familial intrahepatic cholestasis (SPGP/
BSEP/ABCB11) [19], adrenoleukodystrophy (ABCD1)
[20], Stargardt’s disease and age-related macular degener-
ation (ABCR/ABCA4) [21], Tangier disease and familial
hypoalpha-lipoproteinemia (ABCA1) [22,23], and pseudox-
anthoma elasticum (MRP6/ABCC6) [24] are all caused by
mutations in ABC transporter genes. The substrates for
ABC transporters are very diverse, and include natural pro-
duct drugs (ABCB1), lipids (ABCA4, ABCA7, ABCB4),
fatty acids (ABCD1–4), sterols (ABCG5, ABCG8), anionic
conjugates (ABCC1–3), peptides (ABCB2, -3), cyclic nu-
cleotides and nucleoside analogs (ABCC4, -5), and ions
(ABCB6, -7, ABCC7) [http://humanabc.4t.com/humanabc.
htm].
A large body of published data supports the proposal that
ABC transporters transport a large variety of structurally
unrelated substrates by a very similar mechanism, and that
this common aspect of transport resides in regions of high
degree of sequence conservation. Excellent reviews on such
structure/function relationships in ABC transporters have
been published [1–8], and will not be reiterated herein.
Suffice it to say that studies by site-directed mutagenesis,
site-specific modification, epitope mapping with photoac-
tive ligands and studies in chimeras strongly suggest that
TM segments form the substrate-binding site inside the
membrane. On the other hand, the two highly conserved
NBDs have been shown to bind ATP by photolabeling, and
in most cases to display ATPase activity. Both processes are
absolutely required for transport activity, and thought to
underlie the unique substrate-induced ATPase activity seen
in certain ABC transporters (see below). The current work-
ing model for ABC transporters is that ATP binding and
hydrolysis by the NBDs cause structural changes in the TM-
associated substrate binding sites to mediate transport of the
ligand across or within the lipid bilayer. Nevertheless, a
number of important questions on the structure and mech-
anism of action of ABC transporters have remained so far
unanswered or poorly understood. Some of these include (1)
a high resolution structure of one such protein, including
TM segments and membrane associated regions; (2) the
structure of substrate-binding sites capable of accommodat-
ing with high affinity a large number of structurally unre-
lated substrates; (3) the mechanism by which ATP binding
and hydrolysis at either or both NBDs regulate substrate
binding and transport at the MSDs; (4) contribution of each
NBD to ATPase activity in the overall mechanism of trans-
port; (5) dynamic information on structural changes during
the catalytic cycle or transport process.
Large amounts of active protein in a highly pure state are
required to address these issues. Several expression systems
have been used to purify ABC transporter proteins in a
functional state. These include bacterial [25], mammalian
[26,27], baculovirus-infected insect cell [28], and yeast
[29–31] expression systems. In this review, we will sum-
marize some of our work with the yeast P. pastoris, review
unique features of this system, and how it has been used to
successfully express and study three mammalian ABC
transporters, P-glycoprotein (P-gp/ABCB1), and two mem-
bers of the MRP/ABCC subfamily, MRP1 (ABCC1) and
MRP6 (ABCC6). These transporters are associated with the
emergence of multidrug resistance in mammalian cells [2,3],
fungi [32], and protozoans [33], as well as with genetic
defects in human connective tissues in pseudoxanthoma
elasticum (PXE) patients [24].
2. P-glycoprotein (P-gp/ABCB1)
2.1. Introduction
P-glycoprotein (P-gp/ABCB1) was discovered as being
overexpressed and responsible for the multidrug resistance
phenotype of tumor cells selected for high-level resistance
in vitro [34] or appearing during chemotherapy in vivo. P-
gp-expressing cells are resistant to a wide variety of struc-
turally and functionally unrelated cytotoxic drugs, including
natural products Vinka alkaloids, anthracyclines, taxanes,
epipodophyllotoxins, and actinomycin D (reviewed in Ref.
[3]). Three P-gp encoding mdr genes have been detected in
rodents (mdr1, mdr2, mdr3) [35,36] while only two have
been found in humans (MDR1, MDR2) [37,38]. The corre-
sponding P-gps are functionally classified into Class I
(Mdr1, Mdr3, MDR1) and Class II (Mdr2, MDR2), by the
ability of Class I, but not Class II, P-gps to convey multi-
drug resistance upon transfection and overexpression of the
corresponding cDNAs into otherwise drug-sensitive cells
(reviewed in [3]). Much of the early functional studies on P-
gp were carried out in mammalian cells expressing high
levels of P-gp and obtained by stepwise selection and
overexpression of the endogenous MDR/mdr genes or of a
transfected MDR/mdr cDNA [3]. Indeed, transfection of
biologically active MDR/mdr cDNAs into cells followed by
selection for high-level drug resistance in vitro offered an
early advantageous way to isolate cell clones expressing
high levels of P-gp for functional studies. Studies in intact
cells or in sealed membrane vesicles derived from them
have established that P-gp functions as a drug efflux pump
at the plasma membrane that shows amazingly broad sub-
strate specificity. Transport is ATP- and temperature-
dependent, and can be blocked by a number of structurally
unrelated P-gp inhibitors, including calcium channel block-
ers such as verapamil, or immunomodulators such as cyclo-
sporin A [3]. Polarized epithelial kidney cells stably
transfected with MDR/mdr cDNAs and overexpressing
Class I and Class II P-gps have also been used to monitor
trans-epithelial drug transport by P-gp [39]. Studies in these
cells have also demonstrated that the normal physiological
function of P-gp is to act as a lipid transporter, with Class I
P-gp showing broad lipid specificity, while Class II P-gp is
specific for phosphatidylcholine [40]. P-gp displays the
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classical four-domain structure (MSD1–NBD1–MSD2–
NBD2) shared by many members of the ABC transporter
superfamily (Fig. 1A) [3]. Studies with recombinant P-gps
bearing discrete epitope tags inserted into different locations
of the protein, followed by immunodetection in intact or
permeabilized transfected cells [12], have verified the major
topological features of P-gp initially predicted by hydro-
pathy profiling [38,41]. These include 12 TM segments
clustered in two MSDs, two intracellular NBDs, a large
glycosylated extracellular loop, and intracellular C- and N-
termini (Fig. 1A). Peptide mapping with photoactive sub-
strate analogs [42], studies in chimeric [43–45], naturally
occurring [46,47], or experimentally induced [48–53] P-gp
mutants with altered substrate specificities, as well as site-
specific modifications in single-cysteine mutants [54–56],
suggest that the MSDs of P-gp, and of other ABC trans-
porters, form the substrate binding site in the lipid bilayer.
On the other hand, drug transport by Pgp is ATP-dependent,
and P-gp directly binds ATP (reviewed in Ref. [3]). Studies
by site-directed mutagenesis (for example Refs. [57,58]),
site-specific modification in single Cys mutants [59], and
studies in half molecules [60] show that both NBDs are
essential for function, with complete cooperativity between
the two NBDs for ATP hydrolysis and drug transport.
2.2. Expression in various systems
Characterization of P-gp ATPase activity has been car-
ried out using partially or highly purified protein prepara-
tions from different expression systems. In general, ATPase
activity is measured by standard Pi release assay or by the
ability to trap photolabeled nucleotide (8-azido-[32P]ADP)
in a vanadate (Vi)-dependent fashion. Low-level drug-
stimulated ATPase activity was initially reported in crude
membrane fractions from P-gp transfected NIH-3T3 cells
[61]. Using the insect cell (Sf9)/baculovirus expression
system, underglycosylated recombinant P-gp can be over-
expressed and readily detected by SDS-PAGE of crude
membrane fractions followed by Coomassie blue staining
[62]. Membrane vesicles from P-gp-expressing Sf9 cells can
be used directly for transport studies, and P-gp produced in
this system binds drugs [62] and shows vanadate-sensitive
and drug-stimulated ATPase activity [63]. The lytic nature
of the baculovirus infection/expression, although allowing
overexpression of membrane proteins with cytotoxic effects,
limits the amount of protein produced due to its batch mode.
In addition, it is time-consuming to generate the expression
constructs and to obtain sufficiently high viral titers. P-gp
has also been expressed using a vaccinia virus-based system
[64]. One limitation of this system is that the cloning and
selection process involves multiple steps, although the level
of expression of transport-competent P-gp ultimately
reached in infected cells is quite high. Transient or stable
expression of P-gp in HEK293 cells has been favored by
some [65], and offers a reasonably simple and quick
procedure to express wild-type or recombinant isoforms of
P-gp, for transport studies and for biochemical character-
ization, including small-scale purification (see below).
Finally, full-length P-gp has been expressed in E. coli
[66]. Although bacterial expression of Pgp could constitute
a rapid and relatively inexpensive way to produce large
amounts of the protein, the usefulness of this system is
limited by the relative instability of the full-length protein,
the very short half-life, and solubility problems (inclusion
bodies). Nevertheless, expression of functional human P-gp
in protease-deficient E. coli mutants has been reported and
is associated with decreased uptake of tetraphenylphospho-
nium (TPP) in intact cells, and increased ATP-dependent
transport of TPP into inside-out vesicles from these cells
[66]. The low amount of biologically active protein and the
lack of eukaryotic maturation processes in this system have
limited its general applicability. On the other hand, large
amounts of individual NBDs of Pgp have been expressed in
bacterial hosts [25]. These have been purified to homoge-
neity after extraction and solubilization using chaotropic
agents. Although these preparations do not show ATPase
activity, they have been used to study the nucleotide binding
properties of the NBDs as well as their reported interaction
with steroids such as RU486 [25,67].
2.3. Purification from different hosts
P-gp has been purified to homogeneity from a number of
sources (Table 1). Wild-type hamster Pgp was purified from
plasma membrane enriched fractions of a colchicine-resistant
CHO cell line, CHRB30, by a protocol involving isolation of
enriched plasma membrane by sucrose density gradient,
solubilization in Zwittergent 3-12, ion exchange chromatog-
raphy on DEAE cellulose, and immunoaffinity chromatog-
raphy using anti-Pgp monoclonal antibody C494 [26]. P-gp
purified by this protocol shows ATPase activity and is trans-
port-competent once reconstituted in proteoliposomes [26].
Hamster Pgp has also been purified from another CHO cell
line (CR1R12) by a protocol based on solubilization in
octylglucoside/E. coli lipid mixture, absorption on Reactive
Red 120 agarose followed by NaCl gradient elution, and
reconstitution by dialysis [27,68]. Such a preparation (1-mg
purified protein from 10-mg membranes) shows a drug
stimulable ATPase activity of 4.2 Amol Pi/min/mg protein,
and demonstrates vanadate-induced trapping of nucleotide
[27]. On the other hand, recombinant human P-gp bearing a
series of histidine at the C terminus (metal binding site) and
expressed in HEK 293 cells can be easily purified in small
amounts by affinity chromatography. In this protocol, crude
membrane extracts from Pgp-positive cells are solubilized in
n-dodecyl-h-D-maltoside, and further purified by two suc-
cessive chromatography steps on Ni-NTA resins, and eluted
with imidazole (5–10 Ag per 10 100-mm dishes of tran-
siently transfected HEK 293 cells). Such enzyme prepara-
tions show ATPase activity of 1–1.2 Amol Pi/min/mg protein
under full stimulation by verapamil or colchicine [65]. P-gp
purified from Saccharomyces cerevisiae and reconstituted
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into E. coli lipids also exhibits verapamil-stimulated ATPase
activity [69]. In addition, baculovirus-infected insect cells
have also proven to be an excellent source for expression and
purification of functionally active P-gp [70,71], and the yield
of purified P-gp was superior to that obtained from mamma-
lian cells [65,72]. Comparison of the expression and purifi-
cation of P-gp in several expression hosts has been
summarized in Table 1.
2.4. Functional characterization in yeast S. cerevisiae
Our laboratory has turned to yeast as a model organism to
study P-gp structure and function. Yeast offers several advan-
tages over other expression systems for rapid and efficient
genetic analysis, as well as for transport studies and high-
level expression of heterologous proteins. The yeast S.
cerevisiae has an ABC transporter, designated STE6, that
transports the mating pheromone peptide ‘‘a’’ factor; yeast
cells bearing a null mutation at STE6 are sterile and do not
mate with A cells [73]. Expression of the Class I mouse P-gp
mdr3 in a ste6 deletion mutant was shown to restore mating,
suggesting that mdr3 was functional in yeast [74,75]. Addi-
tional studies showed that P-gp could be stably expressed in
the membrane fraction of yeast cells where it bound ATP and
drug analogs (iodoarylazidoprazosin), and importantly, its
expression at this site was concomitant to the appearance of
cellular resistance to the anti-fungal macrolide peptide and
cyclosporin analog FK506 and FK520 [75]. Genetic
approaches have been used to identify structure/function
relationship of P-gp expressed in yeast. For example, studies
in chimeric molecules showed that NBD1 cannot be sub-
stituted by NBD2 in P-gp without loss-of-function, but also
established that most of NBD1 could be substituted by
corresponding segments of NBD2 except for two sets of
discrete residues T578C and ERGA/DKGTat positions 522–
525 near the Walker B motif [76]. Yeast not only permits the
targeted mutagenesis of specific protein segments, but also
allows the implementation of random mutagenesis protocols
coupled to efficient re-cloning of mutagenized segments by
homologous recombination. This approach was used to
systematically mutagenize the first intracellular loop (IC1)
and TM2, -3, and -4 segments of P-gp, leading to the
identification of highly mutation sensitive residues essential
for transport [77]. Importantly, yeast has also proven very
valuable in deciphering the mechanism of transport of P-gp.
Studies in inside-out membrane vesicles purified by lectin
chromatography from P-gp-positive yeast cells demonstrated
that P-gp can transport drugs in a temperature-, time- and
ATP-dependent and osmotically sensitive fashion [78]. The
yeast mutant sec6-4 is defective in the last step of vesicular
fusion and thus accumulates at the nonpermissive temper-
ature large amounts of secretory vesicles (SV) [79]. Such SVs
present a number of advantages including (1) their homoge-
neous size and uniform polarity, (2) they are tightly sealed
and maintain a proton gradient across the membrane gener-
ated by the PMA1 vacuolar H+-ATPase, (3) P-gp can be
inserted in these SVs exposing their catalytic NBDs to the
outside. Finally, temperature-sensitive mutants of PMA1 can
be expressed in these SVs allowing one to monitor the effect
of the DpH on transport function of P-gp [80]. In this system,
it was directly demonstrated that mouse Class I (Mdr1, Mdr3)
but not Class II (Mdr2) P-gps can mediate the accumulation
of radiolabeled drugs vinblastine and colchicine in the SVs.
Drug transport by P-gp was temperature- and ATP-depend-
ent, and was not affected by membrane potential, and trans-
port of a lipophilic cation occurred against a significant
proton gradient. Likewise, vinblastine transport occurred
against a continuously increasing concentration gradient
[81]. These studies were the first to demonstrate that P-gp
acts as a true ATP-dependent drug transporter by a mecha-
nism clearly distinct from a proton symport or antiport
mechanism, which had been previously suggested [82]. Yeast
SVs were also used to demonstrate that the normal physio-
logical role of Class II P-gp (mouse Mdr2) is a phospholipid
Table 1
Comparison of expression and purification of P-glycoprotein in various expression systems
Host Starting materials P-gp content (%) De Purification methods Final yield Purity (%) Lipid Reference
CHO (CHRB30) 3.5 mg PM 16/31 SFI 15 Zwt DE52 IMAC 100 Ag 90 bovine brain PE [26]
CHO (CR1R12) 10 mg PM 16/31 SFI 21 OG Reactive Red
120 agarose
1 mg purea E. coli lipids [27,68]
HEK293 20 10-cm
dish culture
N.A. DM Ni-NTA 6–12 Ag 80 sheep brain PE [65]
S. cerevisiae 20 mg PM <0.5 LPC Ni-NTA 50 Ag 90 E. coli lipids [69]
KB-V1 16 mg PM 3 in DeEx OG CL-6B WGA 30 Ag >90 mixtureb [72]
Baculovirus/insect 500–600 mg PM 3–4 OG Ni-AC 4–6 mg 80 mixtureb [70,71]
P. pastoris 480–600 mg
microsomes
5 DM Ni-NTA DE52 6 mg purea asolectin or
E. coli lipid
[31]
P. pastoris 100 mg microsomes 5 LPC Ni-NTA avidin 700 Ag purea E. coli lipid [90]
Abbreviations: AC: affinity chromatography; De: detergent; DeEx: detergent extract; DM: n-dodecyl-h-D-maltoside; IMAC: immunoaffinity chromatography;
LPC: lysophosphatidylcholine; OG: octyl-h-D-glucopyranoside; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PM: plasma membrane; PS:
phosphatidylserine; SFI: sucrose fraction interphase; WGA: wheat germ agglutinin; Zwt: Zwittergen 3-12.
a Contaminants were not detectable by SDS-PAGE and Coomassie blue staining.
b Mixture of E. coli lipid/PC/PS/cholesterol (w/w 60:17.5:10:12.5) at 1:8 protein/lipid ratio.
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translocase that functions as a lipid flippase mechanism [83].
In these experiments, fluorescently labeled phosphatidylcho-
line (NBD-PC) containing liposomes were fused to P-gp-
positive SVs, and the rate of NBD-PC translocation from the
outer to the inner leaflet was measured by determining the
amount of fluorescence quenched in the presence or absence
of detergent. Mdr2-mediated lipid translocation was specific
for PC, and was not seen for other phospholipids, such as
phosphatidylethanolamine (PE); NBD-PC transport by
Mdr2-positive SVs was ATP-dependent, and inhibited by
verapamil [83]. Later, transport was found stimulated by the
bile acid taurocholate, suggesting a mechanism for the
creation of a physiological PC gradient in the canalicular
domain of hepatocytes [84]. Together, these studies demon-
strate that Class I and Class II P-gps are functional in yeast. In
S. cerevisiae, the overall amount of P-gps expressed is not
very large, and not sufficient for large-scale purification
required for physical and structural studies or for measuring
catalytic parameters of P-gp.
2.5. Overexpression and purification in yeast P. pastoris
The yeast P. pastoris offers a convenient alternative for
such high level of protein expression. P. pastoris is a
methylotrophic yeast capable of metabolizing methanol as
a sole source of carbon. The first enzyme in the methanol
utilization pathway is alcohol oxidase (encoded by AOX1
and AOX2 genes), which converts methanol to formalde-
hyde [85]. When yeast cells are grown with methanol as a
sole source of carbon, the AOX1 enzyme is highly induced
and accounts for 30% of total soluble protein [86]. Intro-
duction of heterologous genes (cDNAs) at the AOX1 locus
by homologous recombination results in very high levels of
mRNA and protein expression of the inserted sequence
upon methanol induction. The expression system is well
developed with a variety of plasmid vectors commercially
available (Invitrogen). For example, the yeast plasmid
vector pHIL-D2 contains sequences allowing replication
and selection in bacterial (AmpR) and yeast (HIS-4) hosts.
The cloning site is flanked by AOX1 chromosomal sequen-
ces that allow for homologous recombination of the cloned
gene into the AOX1 locus of yeast chromosome. Vectors
designed for secretion of recombinant proteins into culture
medium have also been described (Invitrogen). Up to now,
over 200 intracellular, secreted, or membrane proteins from
a variety of sources, including viral, bacterial, plant, and
human proteins, have been successfully expressed in P.
pastoris [87]. Several wild-type or protease-deficient
mutants of P. pastoris strains are available for expressing
proteolysis susceptible proteins, but strains GS115 (his4,
Mut+) and KM71 (arg4, his4 aox1DARG4, Muts) are most
frequently used for expression from a targeted AOX1 gene
copy or from a multicopy episomal plasmid. Typically, P.
pastoris is transformed by a lithium acetate (or chloride)
procedure, followed by selection of transformants on syn-
thetic minimum medium lacking histidine. When the GS115
strain is used, HIS+ transformants are replica-plated on solid
medium with or without methanol as a sole carbon source,
and clones that show slow growing phenotype on methanol-
containing medium (Muts), due to the disruption of the
chromosomal AOX1 locus, are selected and screened for
protein expression by immunoblotting. Early studies
showed that P-gp (Mdr3) could be expressed at high levels
in P. pastoris, accounting for up to 10–15% of membrane
proteins, and easily detected by SDS-PAGE and Coomassie
blue staining [29]. The amount of protein produced is
approximately 10 times higher than that achieved in S.
cerevisiae, and slightly higher than that reached by baculo-
virus-mediated expression in insect cells (Table 1), and at a
fraction of the cost. Also, P. pastoris cells can and have been
grown and induced under fermentor conditions for very
large or industrial scale production [31]. The P. pastoris-
expressed P-gp appears properly folded as it reacts with a
photoactive drug analog [29,30]; in addition, deoxycholate
extracts from membrane fractions (purified by centrifuga-
tion on discontinuous sucrose density gradients, and migrat-
ing at the 16%–31% sucrose interface) of P-gp-expressing
P. pastoris cells reconstituted in E. coli lipids showed
ATPase activity that could be stimulated by verapamil,
valinomycin, and vinblastine (maximum activity 0.20
Amol/min/mg protein), with an optimal pH at 7.7 [29]. This
work suggested that P-gp was indeed active in P. pastoris,
and opened the door to full-scale expression, purification,
and functional characterization studies. For these experi-
ments, the mouse mdr3 cDNA was modified for optimal
expression and easy purification from P. pastoris (pHIL-
mdr3-H6BD). First, the 5Vuntranslated region of the mRNA
was deleted and replaced by a series of six adenosine
residues upstream the AUG, to optimize mRNA translation
in yeast [88]. Second, a series of six histidines was added at
the carboxyl terminus of the protein to allow affinity
purification by nickel affinity chromatography. Third, a
biotin acceptor domain (BD) from oxaloacetate decarbox-
ylase of Klebsiella pneumoniae [89] was fused in-frame at
the C terminus of the protein. This BD domain allows for
biotinylation of the protein in vitro using purified biotin
ligase, which catalyses transfer of biotin from the inter-
mediate, biotinyl-5V-AMP to the unique lysine residue in the
biotin domain. The strong affinity between biotin and avidin
is used to obtain highly purified and biologically active
biotinylated chimeric protein by chromatography on a
monomeric avidin agarose resin [90]. Using the pHIL-
mdr3-H6BD construct, over 90% of the His+/muts trans-
formants were found to express the recombinant P-gp.
Although several related protocols have been described for
P-gp purification from P. pastoris [31,58,90], only one that
uses the recombinant Mdr3-H6BD will be summarized here
[90]. Two-liter culture of P. pastoris/mdr transformants was
induced by transferring the cells to methanol-containing
medium and further incubation for 48–72 h, with methanol
(at 5% final concentration) replenished daily. Crude plasma
membranes were prepared from these cells by lysis using a
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French pressure cell (set at 20000 psi), in the presence of a
cocktail of protease inhibitors and with all steps carried out
at 4 jC. Membrane fractions were separated from unbroken
cells and from majority of cytosolic proteins by low- and
high-speed centrifugation, and were kept at  70 jC in a
storage buffer containing 20% glycerol. A 2-l culture yields,
on average, between 100 and 200 mg of crude membrane
proteins. For each protein purification experiment, mem-
branes are thawed and are biotinylated in vitro for 3 h at 30
jC in a reaction mixture containing ATP, D-biotin (400 AM),
and commercially available biotin ligase (12500 U). The
extent of biotinylation can be followed by immunoblotting
against extravidin–peroxidase. Following biotinylation,
membranes are concentrated by precipitation with MgCl2,
and P-gp is extracted with detergent in a buffer containing
0.6% lysophosphatidylcholine. Solubilized P-gp is then
subjected to a first affinity chromatography with Ni-NTA
resin, to enrich the protein and to eliminate remaining free
D-biotin. For this, the protein is transferred to a buffer
containing 0.1% n-dodecyl-h-D-maltoside, and elution of
the immobilized P-gp from the resin is carried out in the
presence of 80 mM imidazole [90]. The purity of this P-gp
preparation is approximately 75%. Mdr3-H6BD is further
purified by a second affinity chromatography on monova-
lent avidin–Sepharose; for this, a commercially available
monovalent avidin resin is first equilibrated in buffer con-
taining 100 nM D-biotin (to increase specific binding of the
protein of interest), followed by loading of the Mdr3-H6BD
imidazole eluate, and elution with 4 mM D-biotin. This
simple two-step affinity chromatography protocol allows the
rapid and efficient purification of highly pure biotinylated P-
gp, which is devoid of contaminants detected by SDS-
PAGE and by Coomassie blue staining [90] (Table 1). For
reconstitution, the protein is incubated with 1% E. coli lipids
(acetone/ether preparation) followed by dialysis to remove
detergent and D-biotin. P-gp purified in this manner shows a
robust ATPase activity as measured by (a) Pi release, with
Km for ATPf 0.7 mM, and Vmax of 2.43 Amol Pi/min/mg
protein under maximum stimulated conditions (100 AM
verapamil), or (b) by Vi-induced trapping of 8-azido-
[32P]ADP [90]. Alternate protocols based on Ni-NTA affin-
ity chromatography followed by DE52 ion-exchange chro-
matography have been described and yield protein of about
90% homogeneity which exhibits high verapamil-stimulated
ATPase activity (Vmax of 4.2 Amol min 1 mg 1, Kmf 0.7
mM) [31,58]. Similar results were obtained for mouse Mdr3
purification from fermentor-grown P. pastoris [31,58]
(Table 1), and for purification of the human MDR1 P-gp
and its Cys-less mutant [91].
2.6. Biochemical and structural characterization of P-gp
purified from P. pastoris
Highly purified P-gp preparations from P. pastoris have
been used to study the catalytic cycle of P-gp, including the
respective contribution of each NBD in this process. Early
mutagenesis experiments have established that both NBDs
are essential for function, with complete cooperativity
between the two sites for ATP hydrolysis and drug transport
[57,58,61,62]. Two models have been proposed for catalysis
and coupling of ATP hydrolysis to transport. In the ‘‘alter-
nate site’’ catalysis model [92], both NBDs are catalytically
active with equal probability of hydrolysis at NBD1 and
NBD2. In this model, one drug molecule is transported per
ATP molecule hydrolyzed. The experiments that support
this model include Vi-induced nucleotide trapping, in which
equal trapping of nucleotide occurs in NBD1 and NBD2,
with a complete inhibition of ATPase activity occurring with
one molecule of Vi trapped per P-gp molecule [93]. Thus,
when one site enters the transition state (P-gpMgADPPi/
Vi), the other cannot do so, implying alternate hydrolysis. In
the second model, the major difference is that two ATP
molecules need to be hydrolyzed for one substrate molecule
to be transported [94]. This model is based on the observa-
tion that the P-gpMgADPVi-inhibited P-gp has reduced
affinity for drugs [94–96], and that a second ATP hydrolysis
event, after release of MgADPVi, is required to restore
normal drug binding properties [94]. Hence, drug binding
induces hydrolysis of a first ATP and translocation of
substrate to a low affinity site, as well as substrate release,
while hydrolysis of a second ATP is required to recreate a
high affinity drug site. Studies with mutants at homologous
positions in the Walker A (K429R/K1072R) and B (D551N/
D1196N) sequence motifs of NBD1 and NBD2 showed that
alterations at either position completely inactivate the
ATPase activity of P-gp. In addition, no Vi-induced trapping
of 8-azido-ATP could be detected in any of the mutants,
suggesting that the NBDs cannot function independently as
catalytic sites in the intact molecule, but rather that coop-
erative interactions between the two NBDs are absolutely
required for ATP hydrolysis by P-gp [58]. Similar conclu-
sions were reached from the study of additional loss-of-
function mutants at highly conserved serine residues in the
Walker A motif of NBD1 (S430A) and NBD2 (S1073A)
[97]. Interestingly, somewhat different conclusions were
reached from the systematic study of all carboxylate resi-
dues that are highly conserved in the NBDs of all ABC
transporters sequenced to date [11]. Two mutants, E552Q
and E1197Q, although showing no drug-stimulated ATPase
activity (measured by Pi release), showed vanadate trapping
of 8-azido-nucleotide similar to wild type. This suggested
that single site catalysis could occur in these mutants, with
release of MgADP from the NBD being impaired in these
mutants. More recent analyses of these mutants showed that
drug-stimulated nucleotide trapping in E552Q was Vi-
dependent and resembled the wild-type enzyme, while it
is almost completely Vi-insensitive in E1197Q (Carrier and
Gros, unpublished data). Furthermore, these results support
a model in which the two NBDs of P-gp are not functionally
equivalent, with NBD2 showing a faster turnover than
NBD1 [Carrier and Gros, unpublished data]. Additional
structure–function studies have been conducted in a human
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MDR1 mutant lacking all endogenous cysteine residues
[59], and purified from P. pastoris [91]. Using proteins
containing different combinations of naturally occurring
Cys residues, it was demonstrated that an inhibitory intra-
molecular disulfide bond forms between Cys-431 and Cys-
1074, both located in the Walker A sequence motif of NBD1
and NBD2 [91]. This suggests that the two NBDs of P-gp
are structurally very close, and that formation of such a
disulfide bond in vivo could (in principle) underlie a
regulatory mechanism for P-gp activity. Finally, prepara-
tions of biotinylated P-gp purified from P. pastoris have
been used to study the interaction of P-gp with chemical
inhibitors that are known to block drug transport [90]. Using
a series of 1,4-disubstituted piperazine derivatives with a
central chiral carbon, it was observed that all these inhibitors
can stimulate P-gp ATPase activity in a dose-dependent
fashion. Furthermore, it was observed that some of the
compounds are also capable of inhibiting either vinblastine
or verapamil stimulation of ATPase activity in an enan-
tiomer-specific fashion, suggesting complex interactions at a
single substrate binding site on P-gp [90].
Currently, there is no high-resolution structural informa-
tion available for P-gp, although a 2.5-nm [98] and a 10-A˚
structure [99] of P-gp purified from CHO cells have been
reported. The former was obtained by single particle anal-
ysis of detergent solubilized protein as well as by Fourier
projection maps of small two-dimensional crystalline arrays,
while the later was by electron microscopy of two-dimen-
sional protein crystals. Three distinct conformations,
namely, nucleotide-free, nucleotide-bound, and post-hydro-
lytic transition state, were observed during catalytic process
[99]. The nucleotide-free state of P-gp has its two MSDs
forming a chamber within the membrane. Nucleotide bind-
ing to the NBDs induces repacking of the MSDs and
reduction in drug binding affinity. The third distinct con-
formation of the protein was observed in the post-hydrolytic
transition state prior to the release of ADP/Pi.
P-gp preparations purified from P. pastoris are also
started to be used for structural studies. Nucleotide-induced
conformational changes in P-gp and its NBD mutants (in
Walker A and B motifs from NBD1 and NBD2) were
recently analyzed by limited trypsin digestion of proteins
purified from P. pastoris, followed by epitope mapping
using monoclonal antibodies that recognize both or either
NBDs in P-gp [100]. A unique trypsin digestion profile
indicative of trypsin resistance was observed under condi-
tions of Vi-induced trapping of nucleotides. Under such
conditions the trypsin sensitivity profiles of double P-gp
mutants K429R/K1072R and D551N/D1196N and of single
mutants K429R, K1072R, and D1196N were very similar
and clearly distinct from the wild-type protein. In contrast,
under Vi-induced nucleotide trapping conditions, the
D551N mutant showed a trypsin sensitivity profile similar
to that of wild type. This raised the possibility that structural
and functional differences exist between the two NBDs,
including different sensitivity to Vi and hence possible
differences in catalytic activity [100]. More recently, struc-
tural information on P-gp purified from P. pastoris was
obtained by attenuated total reflection Fourier Transform
Infrared (ATR-FTIR) spectroscopy, including conforma-
tional changes induced by nucleotide binding and hydrol-
ysis [101]. In these experiments, also included for study
were Walker B mutants, E552Q and E1197Q, that have
impaired ATPase activity due to their inability to release
ADP and/or Pi, but that appear to undergo single site
turnover [11] (Carrier and Gros, unpublished data). P-gp
reconstitution into proteoliposomes (inside-out orientation)
was achieved by mixing the purified protein with detergent-
destabilized asolectin liposome, followed by detergent
removal and sucrose gradient fractionation. The reconsti-
tuted wild-type P-gp proteoliposomes exhibited drug-stimu-
lated ATPase activity, and P-gp was transport-competent
[101]. The secondary structure of wild-type P-gp evaluated
by IR spectrum was found to contain 46% a-helices, 18%
h-sheets, 8% h-turns, and 28% random structures. In the
case of wild-type P-gp, comparison of H/D exchange rates
for nucleotide-free, and MgATP-, or MgATP+Vi-bound P-
gp shows that a major conformational change occurs in the
protein (conformation B) upon inhibition by Vi. This con-
formational change is also seen in the E552Q mutant
analyzed in a similar fashion but, in contrast to wild-type
P-gp, in this mutant conformation B is observed both in the
presence (MgATP+Vi) and absence of Vi (MgATP alone).
On the other hand, this structural change is never observed
in the E1197Q mutant under any of the conditions tested.
This apparent difference clearly indicates an asymmetric
structure and possibly different functions of the two NBDs
of P-gp in the catalytic cycle [101]. Finally, our laboratory
has recently created a P-gp mutant devoid of tryptophan
residues [102]. In mammalian cells, this mutant retains the
ability to convey multidrug resistance, albeit at a reduced
level when compared to the wild-type protein. This mutant
was expressed and successfully purified from P. pastoris.
Therefore, single tryptophan insertion constructed on this
Trp-less backbone and purified from P. pastoris should
prove very useful to obtain, by fluorescence spectroscopy,
dynamic information on structural changes associated with
drug or nucleotide binding and hydrolysis.
3. MRP1/ABCC1
3.1. Introduction
MRP1/ABCC1 was the first identified member of the
MRP/ABCC subfamily, and was discovered as a gene
overexpressed in the P-gp-negative multidrug resistant lung
tumor cell line H69AR [103]. Subsequent transfection
studies demonstrate that overexpression of MRP1 does
confer multidrug resistance in otherwise sensitive cultured
cells by an energy-dependent drug efflux mechanism
[104,105]. Although sequence analyses clearly identity
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MRP1 as part of the ABC transporter family, significant
differences in their predicted NBDs, as revealed by multiple
sequence alignment, have placed MRP1 and a cluster of
other ABC transporters in a separate subgroup, ABCC [2,5]
[http://humanabc.4t.com/humanabc.htm]. The MRP/ABCC
subfamily contains at least 12 members, including MRP1 to
MRP9, the chloride channel CFTR, and the sulfonylurea
receptors SUR1 and SUR2 [6,106,107]. The NBDs of this
sub-group of proteins are characterized by the absence of
11–14 amino acid residues between Walker A and Walker B
motifs of NBD1, compared to the corresponding region of
P-gp and other ABC transporters. In addition, the two NBDs
of the MRP/ABCC subfamily are more divergent than those
of P-gp [2,5]. The apparent evolutionary distance between
the two NBDs of the MRP/ABCC subgroup is paralleled by
a nonequivalent role of the two NBDs in the catalytic action
of the protein, as supported by a large body of published
biochemical data (see below). In addition, hydropathy pro-
filing of the MRP/ABCC subgroup identifies the presence
of a unique amino terminal membrane associated region
(MSD0) in addition to the classical (MSD1–NBD1–
MSD2–NBD2) core structure shared by many ABC trans-
porters (Fig. 1C). Epitope mapping and topology studies
have established that this additional amino terminal mem-
brane region is most likely composed of five TM segments,
which would place the amino terminus of the protein
extracellularly on a glycosylated segment [13,108]. This
extra N-terminal MSD0 is present in some members of the
MRP subfamily, including MRP1, -2, -3, -6, and SUR1 and
SUR2 (Fig. 1C), and absent in others, like MRP4, -5, and
CFTR (Fig. 1B) [5,6]. The topology of the newly discovered
MRP7, MRP8, and MRP9 has not been well characterized.
The importance of the MRP/ABCC family in normal
physiology is highlighted by the discovery of disease-caus-
ing mutations in several inherited genetic disorders, includ-
ing cystic fibrosis (CFTR/ABCC7) [17], Dubin–Johnson
syndrome (cMOAT/MRP2/ABCC2) [18], pseudoxanthoma
elasticum (MRP6/ABCC6) [24,109,110], and familial per-
sistent hyperinsulinemic hypoglycemia of infancy (SUR1/
ABCC8) [111]. In addition, increased expression of MRP1/
ABCC1 in multidrug resistant cancer cells in vitro, as well
as in tumor isolates in vivo, suggests major clinical rele-
vance and has generated much interest in this gene and
protein for potential intervention in treatment of drug
resistant cancers with specific inhibitors [2,5]. MRP1 shows
many similarities with P-gp but also displays unique and
distinguishing structural (see above) and functional charac-
teristics that have helped identification of structure/function
relationships in both proteins. The drug resistance profile of
MRP1-overexpressing cells has been investigated exten-
sively, and found to be similar but not identical to that of
multidrug resistant P-gp. Indeed, overexpression of P-gp
and MRP1 confers cellular resistance to many of the same
cytotoxic drugs, including anthracyclins, Vinka alkaloids,
and epipodophyllotoxins, and mitoxantrone. In general, the
level of drug resistance imparted by P-gp towards these
drugs seems to be higher than those conferred by MRP1
(reviewed in Refs. [2,5,6]). More importantly, each protein
confers resistance to a unique set of compounds such as
colchicine and taxol for P-gp [3,4], and arsenite and anti-
mony for MRP1 [2,3,5,6]. Both MRP1 and P-gp transport
drugs at the expense of ATP, and convey drug resistance by
a seemingly related drug efflux mechanism. An important
difference, however, is that while P-gp can transport
unmodified cationic lipophilic cytotoxic drugs directly,
MRP1 can transport organic anions, such as drugs conju-
gated with glutathione, glucuronide, and sulfate, and
uniquely co-transports certain unmodified drugs together
with glutathione (GSH) [2,5,6]. In addition to multiple
anticancer drugs, MRP1 is known to transport physiologi-
cally important substrates, such as bilirubin glucuronide,
glucuronide, and sulfate-conjugated bile salts, glutathione
disulfide (GSSG), 17-h-estradiol, and the GSH-conjugates
of prostaglandin A2 [5,112]. One well-characterized phys-
iological substrate of MRP1 is cysteinyl leukotriene LTC4,
which is an important mediator of inflammatory responses.
LTC4 is the highest affinity substrate of MRP1 identified so
far [5]. Interestingly, MRP1 was recently shown capable of
translocating lipid molecules, regulating lipid asymmetry in
certain types of physiological membranes such as those of
erythrocytes [113,114]. Therefore, MRP1 may share with P-
gp a similar lipid flippase mechanism of action.
Biochemical and functional characterization of MRP1 has
been mostly carried out in drug-selected mammalian cells
overexpressing either an endogenous or a transfected copy of
the MRP1 gene, and in Sf9 insect cells overexpressing a
corresponding recombinant baculovirus (reviewed in Refs.
[2,4–6]). Like P-gp, photolabeling studies have shown that
MRP1 can directly interact with drug substrates, and that TM
segments play a key role in such interactions. Indeed, MRP1
can be photolabeled by analogs of leukotriene C4 (LTC4)
[115], as well as by photoactive analogs of a quinoline
(IACI) [116] and Rhodamine (IAARh123) [117]. Studies
with the latter two compounds have identified photolabeling
sites in the second (MSD1) and third (MSD2) large mem-
brane associated portions of the protein [118]. In membrane
fractions, MRP1 can be photolabeled by 8-azido-[a-32P]ATP
in the presence of magnesium and Vi [119]. Vanadate-
induced nucleotide trapping in MRP1 can be stimulated by
anticancer drugs and by glutathione, a first indication that
MRP1 may possess substrate-stimulated ATPase activity
[119]. Studies with MRP1 purified and reconstituted in
liposomes have confirmed that MRP1 has intrinsic ATPase
activity, which is vanadate-sensitive, and can be further
stimulated by drug substrates, glutathione and LTC4
[120,121], although large differences in Km and Vmax were
reported in these studies. Both NBD1 and NBD2 are
required for ATP hydrolysis by MRP1, as mutations in the
Walker A and B motifs in either site drastically reduce ATP
hydrolysis and transport by the protein [121,122]. Moreover,
MRP1 ATPase activity can be significantly stimulated by
certain nucleotide diphosphates [123]. Additional photolab-
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eling studies of wild-type, mutant variants, and half mole-
cules of MRP1 with 8-azido-[a-32P]ATP or 8-azido-
[g-32P]ATP strongly suggest that the two NBDs are not
functionally equivalent in MRP1 but may allosterically
interact. Indeed, it appears that MRP1 exclusively binds to
8-azido-[a- or g-32P]ATP at NBD1 while hydrolysis prefer-
entially takes place at NBD2 [121,122,124].
Structural information on MRP1 is limited and has just
started to emerge. The secondary structure and possible
conformational changes caused by interaction with sub-
strates and nucleotides have been investigated by infrared
spectroscopy (ATR-FTIR) [125]. Ligand binding did not
affect the MRP1 secondary structure but increased accessi-
bility to solvent, suggesting conformational change similar
to that seen with P-gp analyzed in a similar fashion [101].
Using acrylamide quenching of natural tryptophan fluores-
cence to monitor conformational changes, it was observed
that binding of MRP1 drug substrates (and not others)
favors a conformational change upon ATP binding, suggest-
ing that drug substrate-induced conformational changes may
be a requirement for the transport process [125]. A 22-A˚
structure of MRP1 was recently obtained by EM analysis of
2-D crystals [126], and suggests many similarities with P-gp
[126]. These include a monomeric toroidal ring structure
with a large stain-filled central region, and two pseudosym-
metric domains, presumably corresponding to the two
NBDs and located at the cytoplasmic face. Reconstitution
of MRP1 into crystalline protein/lipid arrays allowed detec-
tion of dimeric protein, although it is uncertain whether
MRP1 is dimeric in native membrane [126].
3.2. Overexpression and functional characterization in P.
pastoris
The systematic study of common and distinct aspects of
drug transport by MRP1 and by P-gp would be greatly
facilitated by an experimental system where large amounts
of biologically active protein can be produced for purifica-
tion. Likewise, obtaining structural information on MRP1 in
a dynamic fashion during transport or ATP hydrolysis also
requires large amounts of purified protein. Following the
successful expression, characterization, and purification of
P-gp from overexpressing P. pastoris yeast cells, the expres-
sion of MRP1 in this yeast was attempted. An experimental
strategy similar to that used for P-gp was implemented
[127]. The human MRP1 cDNA was modified by the
deletion of all 5V and 3V untranslated sequences, with
insertion of six consecutive adenosine residues immediately
upstream the ATG initiation codon to enhance translation
efficiency [88]. A hemagglutinin HA epitope tag and six
consecutive histidine residues were added in-frame at the C
terminus for identification of the recombinant protein in
yeast and to facilitate future purification procedures, respec-
tively [127]. The recombinant MRP1 protein was success-
fully expressed from the pHIL-D2 plasmid construct in two
P. pastoris strains, GS115 (his4, Mut+) and KM71 (arg4,
his4 aox1DARG4, Muts). Immunoblotting experiments indi-
cated that MRP1 was expressed as a 165-kDa underglyco-
sylated protein species, which is of significantly faster
electrophoretic mobility than its counterpart overexpressed
in drug-resistant HeLa/MRP1 transfectants [14]. Compara-
tive immunoblotting with crude membrane fractions indi-
cated that the P. pastoris/MRP1 membranes expressed about
30 times more MRP1 protein per weight than their mamma-
lian HeLa/MRP1 counterpart. For large-scale preparation of
membrane fractions to be used for biochemical character-
ization, 2-l cultures of P. pastoris cells were induced with
methanol for 72 h, after which the cells were collected and
lysed using a French pressure cell. Crude membranes were
isolated by successive centrifugation. The ATP binding and
ATP hydrolysis properties of MRP1 were analyzed using 8-
azido-[a-32P]-ATP, under binding (4 jC) or hydrolysis (37
jC) conditions. In contrast to P-gp, ATP binding to the
protein was found to be dependent on the presence of Mg2 +
ions, and sensitive to EDTA; binding was specific and was
competed by excess of both cold ADP and ATP. Under
hydrolysis conditions, vanadate could induce nucleotide
trapping into MRP1, which was temperature-dependent
and required the presence of Mg2 + ions. Vanadate-induced
trapping of nucleotide into MRP1 could be stimulated by
drugs such as vinblastine and vincristine, and by LTC4.
These results strongly suggested that MRP1 was functional
in yeast membranes, and could carry out substrate-stimu-
lated ATP hydrolysis [127]. In addition, a transport assay for
MRP1 using [3H]-LTC4 was designed. In this assay, vesicles
are created from enriched membrane fractions and incubated
with ligand in the presence or absence of an ATP regenerat-
ing system. The effect of MRP1 on accumulation of [3H]-
LTC4 was measured over time by a standard rapid filtration
assay. MRP1 induced time-, concentration-, and ATP-
dependent accumulation of [3H]-LTC4 in membrane
vesicles, establishing that MRP1 expressed in P. pastoris
is indeed functional [127]. Finally, interactions between
MRP1 protein and its potential substrates were investigated
in P. pastoris membranes using a photoaffinity labeling
approach. It was determined, as for MRP1 expressed in
mammalian cell membranes [118], that MRP1 expressed in
P. pastoris binds a photoactive derivative of the fluorescent
MRP1 substrate Rhodamine 123, [125I]-IAAR. Binding was
found to be specific and saturable, and could be effectively
competed by several known MRP1 substrates/modulators,
including LTC4 and MK571 [127]. Taken together, these
results proved that P. pastoris is an efficient expression
system for overexpression and biochemical characterization
of MRP1. Although experimental data for purification of
MRP1 from P. pastoris have not yet been documented, thus
making direct comparison of the yield of pure MRP1 protein
between P. pastoris and other expression systems unavail-
able, the high level of the recombinant protein produced in
P. pastoris provides an optimistic future for large-scale
purification and reconstitution studies and for structural
analysis.
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4. MRP6/ABCC6
4.1. Introduction
Several members of the MRP/ABCC subfamily function
as glutathione conjugate (GS-X) pumps that play key
physiological roles. For example, MRP2 (cMOAT) is
expressed in the canalicular domain of hepatocytes where
it transports a wide range of anionic conjugates into the
biliary space [128], and mutations in MRP2 cause Dubin–
Johnson syndrome in humans [18]. Transfection of MRP2
causes resistance to natural product drugs and to cisplatinum
[129,130]. Likewise, MRP3 transports glucuronide conju-
gates and methotrexate [131], and MRP3 overexpression in
transfected cells causes low-level resistance to VP16 and
teniposide [132]. On the other hand, MRP4 and MRP5 can
transport cyclic nucleotides cGMP and cAMP [133–135],
and overexpression of either protein causes resistance to the
antiviral nucleoside analog 9-(2-phosphonyl methoxyethy-
l)adenine (PMEA), and to anticancer thiopurines, 6-mercap-
topurine (6-MP) and thioguanine [133,135,136].
A poorly characterized but clinically relevant MRP
family member is MRP6 [137,138]. The human MRP6 gene
maps immediately adjacent of MRP1 on human chromo-
some 16p13 [139]. The human MRP6 encodes a protein of
1503-amino-acid residues, which share 45% identity and
55% similarity with MRP1, its most closely related MRP
homologue, suggesting that both genes may have emerged
from a recent gene duplication event. Expression of MRP6
mRNA was found increased in certain drug-resistant cell
lines, but was always concomitant to increased expression
and amplification of the neighbouring MRP1 gene [139].
Despite close sequence identity with MRP1, MRP6 does not
appear capable of conferring drug resistance in transfected
mammalian cells (Cai and Gros, unpublished data). Studies
in membrane vesicles from rMrp6-expressing Sf9 cells
indicate that unlike MRP1 and MRP2, rMrp6 does not
transport glucuronide, sulfate, or glutathione conjugates
[138]. So far, the only identified transport substrate for
rMrp6 is the cyclic pentapeptide endothelin-1 receptor
antagonist BQ123 (cyclo[D-Trp-D-Asp-L-Pro-D-Val-L-Leu]),
though endothelin-1 itself is not a substrate [138].
Recently, human MRP6 (ABCC6) was found mutated in
patients with pseudoxanthoma elasticum (PXE) [24,109,
110]. PXE is a inherited disorder of connective tissues,
characterized by calcification of elastic fibers in skin, arte-
ries, and retina that results in dermal lesions with associated
loss of elasticity, arterial insufficiency, and retinal bleeding
leading to macular degeneration [140]. Mutational analysis
of MRP6 in PXE patients identified large and small dele-
tions, splicing mutations, nonsense mutations, and a number
of missense mutations [24,109]. Interestingly, most of the
single amino acid substitutions mapped in NBD2 of MRP6.
Recently, a rare MRP6 mutation (R1268Q) in a PXE patient
was found to be associated with type IV hyperlipidemia and
hypoalphalipoproteinemia, suggesting that MRP6 may be a
determinant of plasma lipoproteins [141]. Expression stud-
ies of MRP6 mRNA by RT-PCR in tissues affected in PXE
patients have revealed low MRP6 expression in skin, retina,
vessel walls, and placenta [24]. The human MRP6 protein is
expressed at the basolateral membrane of kidney proximal
tubules as well as in liver hepatocytes. However, no MRP6
protein expression is detected in sections of human skin and
retina [110], the tissues affected in PXE patients. In rat
tissues, the Mrp6 protein was detected in lateral and, to a
lesser extent, canalicular membranes of hepatocytes [138].
Interestingly, a recent study revealed that human MRP6
was able to mediate ATP-dependent transport of at least
two anionic glutathione conjugates, N-ethylmaleimide S-
glutathione (NEM-GS) and LTC4, and this transport activ-
ity was inhibited by probenecid, benzbromarone, and
indomethacin [142], suggesting some functional similarity
with MRP1 and MRP2. Moreover, three PXE mutations
were found to abolish the transport activity of MRP6,
suggesting that loss of transport function in these mutants
was the direct cause for the PXE phenotype [142]. Despite
this initial functional study, the substrate specificity, mech-
anism of transport, and role of MRP6 in PXE still remain
largely unknown.
4.2. Overexpression and functional characterization in P.
pastoris
To get an insight into the catalytic activity of Mrp6, our
group has introduced the rat mrp6 cDNA into P. pastoris,
and several clones that express high levels of Mrp6 recombi-
nant protein were isolated [143]. Membrane proteins isolated
from rat Mrp6-overexpressing P. pastoris cells were photo-
affinity labeled with 8-azido-[a-32P]ATP followed by UV
cross-linking. The results showed that, under nucleotide
binding conditions, Mrp6 is able to bind ATP in a Mg2 +-
dependent and EDTA-sensitive fashion, with an affinity
apparently greater than MRP1. ATP binding by Mrp6 can
be supported by other divalent cations, such as Ni2 +, Co2 +,
and Mn2 +, in a manner similar to that seen for MRP1.
However, under hydrolysis conditions, characteristics of
nucleotide trapping induced by transition state analogs into
Mrp6 showed important differences when compared to
MRP1, with respect to divalent cation requirement and
selectivity for transition state analogs. For example, Vi can
induce trapping of 8-azido-nucleotide in MRP1 in the
presence of a number of divalent cations, including Mg2 +
[127]. In contrast, Vi-induced nucleotide occlusion in rMrp6
occurs only in the presence of Ni2 +. On the other hand,
stimulation of nucleotide trapping by Mrp6 can be observed
in the presence of another transition state analog, beryllium
fluoride (BeFx). Such differences in nucleotide trapping
properties of MRP1 and Mrp6 suggest possible structural
differences between the NB sites of the two proteins [143].
One important yet intriguing question onMrp6 function is,
what substrates does it transport if not anticancer drugs?
Mrp6 can transport the anionic cyclopentapeptide and endo-
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thelin-receptor antagonist BQ-123 in vitro, which is also a
substrate of Mrp2 [138]. The affinity for BQ-123 (Kmc 17
AM) by Mrp6 is about sevenfold higher compared to that by
Mrp2 (Kmc 124 AM), suggesting that Mrp6 may be
involved in hepatocellular transport of cyclic oligopeptides
[138]. Other known substrates for Mrp2, including GS-DNP
and LTC4, are apparently not transported byMrp6. This result
is in apparent contrast to those recently obtained with the
humanMRP6 protein [142]. The dual localization of Mrp6 in
lateral and canalicular membranes of hepatocytes is also
difficult to reconcile with an exclusive role in biliary excre-
tion [138]. In an effort to characterize substrate-binding
properties of Mrp6, a photoaffinity labeling approach was
implemented using membrane preparations from Mrp6-
expressing P. pastoris cells and [125I]-IAAR (iodoarylazido
Rhodamine 123) as a potential ligand [143]. It was observed
that Mrp6 could bind the Rhodamine 123 analogue in a
fashion similar to MRP1. [125I]-IAAR binding to Mrp6 is
concentration-dependent and saturated at approximately 4
AM. It is interesting to note that [125I]-IAAR binding to Mrp6
is competed by several drugs, including vinblastine, doxor-
ubicin, and MRP1 modulator, MK571, and is stimulated by
the only known substrate of Mrp6, BQ123. Moreover, the
binding appears unaffected by LTC4, the high affinity sub-
strate of MRP1, as well as by the anticancer drug VP16 [143].
These results suggest important similarities and unique differ-
ences in the ligand binding properties of MRP1 and Mrp6
[127,143]. In addition, these photoaffinity labeling studies
using P. pastoris-expressed Mrp6 provide a rational basis for
the systematic testing of candidate substrates for Mrp6. More
broadly, the ATP binding and hydrolysis assays described for
P. pastoris-expressed Mrp6 can be used to further character-
ize the molecular basis of the apparent loss-of-function
mutations seen in PXE patients.
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